Novartis Gains Next-Generation Gene Therapy Tech With Kate Acquisition

 
• By Jessica Merrill

The Swiss pharma acquired Kate Therapeutics for up to $1.1bn, gaining preclinical gene therapies for neuromuscular conditions and novel platform technology.

(Shutterstock)

More from Gene Therapies

More from Advanced Therapies